Levetiracetam in children with refractory status epilepticus.
The objective of this study was to investigate the utility of levetiracetam (LEV) in children with refractory status epilepticus (RSE). Records of children with RSE who received LEV as adjunctive therapy were reviewed. Over a 7-year period, 11 children had received LEV for RSE. Age ranged from 2 days to 9 years (median = 2.5 months). Prior to administration of LEV, the number of anticonvulsants used to treat RSE ranged from 2 to 7 (median = 3). Starting doses of LEV ranged from 15 to 70 mg/kg (median = 30 mg/kg). LEV was felt to be of benefit in 45% (5/11) of cases, resulting in either resolution of RSE or successful weaning of patients off continuous infusions of other anticonvulsants. In 27% (3/11), response to LEV was unclear as other medications were either added or increased concomitantly with LEV use. The median latency to cessation of RSE following LEV initiation was 1.5 days (range = 1-8 days). All responding patients were on LEV doses >or= 30 mg/kg/day (median 40 mg/kg/day). No significant adverse effects of LEV were reported. LEV may be an effective and safe adjuvant therapy in children with RSE.
Gallentine
William B
WB
Department of Pediatrics (Neurology), Duke University Medical Center, Durham, NC 27710, USA. galle005@mc.duke.edu
Hunnicutt
Addie S
AS
Husain
Aatif M
AM
D000293:Adolescent; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007441:Intubation, Gastrointestinal; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013226:Status Epilepticus / Q000188:drug therapy*
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam